



## 1 **B. Opinions Regarding Lost Profits**

2 Section 284 of Title 35 provides for the award of damages upon a finding of patent  
3 infringement in an amount “adequate to compensate for the infringement, but in no event less  
4 than a reasonable royalty for the use made of the invention by the infringer, together with  
5 interest and costs as fixed by the court.” The Supreme Court has determined that “damages  
6 adequate to compensate” means full compensation for any damages the patent holder suffered as  
7 a result of the infringement. Gen. Motors Corp. v. Devex Corp., 461 U.S. 648, 654 (1983). Lost  
8 profits are recoverable if the patent holder shows a causal link between the infringement and the  
9 loss of profits. BIC Leisure Prods., Inc. v. Windsurfing Int’l, Inc., 1 F.3d 1214, 1218 (Fed. Cir.  
10 1993).

11 The patent holder has the initial burden of showing a reasonable probability that,  
12 “but for” the infringement, it would have made additional sales. Crystal Semiconductor Corp. v.  
13 TriTech Microelectronics Int’l, Inc., 246 F.3d 1336, 1353 (Fed. Cir. 2001). The “but for”  
14 inquiry requires a reconstruction of the market as it would have developed absent the infringing  
15 product.

16 Reconstructing the market, by definition a hypothetical enterprise, requires the  
17 patentee to project economic results that did not occur. To prevent the  
18 hypothetical from lapsing into pure speculation, this court requires sound  
19 economic proof of the nature of the market and likely outcomes with infringement  
20 factored out of the economic picture. . . . Within this framework, trial courts, with  
21 this court’s approval, consistently permit patentees to present market  
22 reconstruction theories showing all of the ways in which they would have been  
23 better off in the “but for world,” and accordingly to recover lost profits in a wide  
24 variety of forms.

25 Grain Processing Corp. v. Am. Maize-Prods. Co., 185 F.3d 1341, 1350 (Fed. Cir. 1999) (internal  
26 citations omitted).

In order to calculate the profits lost by Avocent as a result of Belkin’s  
infringement, Dr. Kerr analyzed the real world KVM switch market to determine each

1 competitor's market share, determined that there were no acceptable non-infringing substitute  
2 products to which Belkin's customers could turn, and apportioned Belkin's market share to its  
3 competitors in proportion to their real world market share. Dr. Kerr then determined Avocent's  
4 per unit profit margin and calculated its lost profits. The Federal Circuit has found this exact  
5 methodology acceptable as a means of proving lost profits in patent litigation. See Crystal  
6 Semiconductor Corp. v. TriTech Microelectronics Int'l, Inc., 246 F.3d 1336, 1354-56 (Fed. Cir.  
7 2001); Grain Processing, 185 F.3d at 1350 (citing with approval State Indus., Inc. v. Mor-Flo  
8 Indus., Inc., 883 F.2d 1573 (Fed. Cir. 1989)).

9 Belkin, however, identifies a number of shortcomings in the data Dr. Kerr used to  
10 calculate market share and argues that some of his assumptions and estimates artificially inflate  
11 Avocent's lost profit claim. In Daubert v. Merrell Dow Pharm., Inc., 509 U.S. 579 (1993), the  
12 Supreme Court charged trial judges with the responsibility of acting as gatekeepers to prevent  
13 unreliable expert testimony from reaching the jury. The gatekeeping function applies to all  
14 expert testimony, not just testimony based on science. Kumho Tire Co. v. Carmichael, 526 U.S.  
15 137 (1999). To be admissible, expert testimony must be both reliable and helpful. The  
16 reliability of expert testimony is judged not on the substance of the opinions offered, but on the  
17 methods employed in developing those opinions. Daubert, 509 U.S. at 594-95. In general, the  
18 expert's opinion must be based on principles, techniques, or theories that are generally accepted  
19 in his or her profession and must reflect something more than subjective belief and/or  
20 unsupported speculation. Daubert, 509 U.S. at 590. The testimony must also be "helpful," such  
21 that a valid connection between the opinion offered and the issues of the case exists. Daubert,  
22 509 U.S. at 591-92.

23 Belkin's objections do not go to the methods or techniques Dr. Kerr used to  
24 calculate lost profits. Rather, Belkin argues that some of the underlying data is so speculative  
25 that the resulting calculation represents no more than Dr. Kerr's subjective belief or declaration.  
26

1 For example, Belkin points out that (a) the market share data on which Dr. Kerr relies comes  
2 from unauthenticated third-party analyst reports that cover only five of the nine years at issue  
3 and (b) Dr. Kerr fails to utilize the best information available when he calculates Avocent  
4 Redmond and Avocent Huntsville's market shares by adjusting revenues rather than simply  
5 comparing the number of units sold. Dr. Kerr's data is not unassailable: it would, of course, be  
6 preferable to have audited annual sales data in a per unit format from every market participant,  
7 minutely adjusted to account for all variations in product and customer base before attempting to  
8 calculate real world market share. Neither Daubert nor the relevant patent cases require  
9 unassailability, however. As noted above, market reconstruction is an inherently hypothetical  
10 undertaking and will require certain assumptions, postulations, and theories to carry us from the  
11 real world to the "but for" world. As long as inferences the expert draws are reasonable,  
12 something less than perfection will be sufficient. The patent holder must demonstrate only that  
13 there is a reasonable probability that, but for the infringement, it would have made additional  
14 sales. Mor-Flo Indus., 883 F.2d at 1577. It need not prove lost sales to a certainty or "negate *all*  
15 possibilities that a purchaser might have bought a different product or might have foregone the  
16 purchase altogether." Paper Converting Machine Co. v. Magna-Graphics Corp., 745 F.2d 11, 21  
17 (Fed. Cir. 1984) (emphasis in original). Belkin may cross-examine Dr. Kerr regarding the  
18 myriad shortcomings in his data and the effects alternative assumptions would have had on his  
19 lost profit opinions. It has not, however, shown that the lost profits testimony is inadmissible  
20 under Daubert.

### 21 **C. Opinions Regarding Reasonable Royalty Rate**

22 With regards to any Belkin sales that do not result in an award of lost profits,  
23 Avocent seeks a "reasonable royalty for the use made of the invention by the infringer." 35  
24 U.S.C. § 284. The reasonable royalty rate is derived from a hypothetical negotiation between  
25 the patent holder and the infringer at the time the infringement began. The goal of the exercise  
26

1 is “to discern the value of the patented technology to the parties in the marketplace when  
2 infringement began.” LaserDynamics, Inc. v. Quanta Computer, Inc., 694 F.3d 51, 76 (Fed. Cir.  
3 2012). “A comprehensive (but unprioritized and often overlapping) list of relevant factors for a  
4 reasonable royalty calculation appears in Georgia-Pacific Corp. v. United States Plywood Corp.,  
5 318 F. Supp. 1116, 1120 (S.D.N.Y. 1970).” ResQNet.com, Inc. v. Lansa, Inc., 594 F.3d 860,  
6 869 (Fed. Cir. 2010). The factors are:

- 7 1. The royalties received by the patentee for the licensing of the patent in suit,  
8 proving or tending to prove an established royalty.
- 9 2. The rates paid by the licensee for the use of other patents comparable to the  
10 patent in suit.
- 11 3. The nature and scope of the license, as exclusive or non-exclusive; or as  
12 restricted or non-restricted in terms of territory or with respect to whom the  
13 manufactured product may be sold.
- 14 4. The licensor's established policy and marketing program to maintain his patent  
15 monopoly by not licensing others to use the invention or by granting  
16 licenses under special conditions designed to preserve that monopoly.
- 17 5. The commercial relationship between the licensor and licensee, such as, whether  
18 they are competitors in the same territory in the same line of business; or  
19 whether they are inventor and promoter.
- 20 6. The effect of selling the patented specialty in promoting sales of other products  
21 of the licensee; that existing value of the invention to the licensor as a  
22 generator of sales of his non-patented items; and the extent of such  
23 derivative or convoyed sales.
- 24 7. The duration of the patent and the term of the license.
- 25 8. The established profitability of the product made under the patent; its  
26 commercial success; and its current popularity.
9. The utility and advantages of the patent property over the old modes or devices,  
if any, that had been used for working out similar results.
10. The nature of the patented invention; the character of the commercial  
embodiment of it as owned and produced by the licensor; and the benefits  
to those who have used the invention.
11. The extent to which the infringer has made use of the invention; and any  
evidence probative of the value of that use.

- 1 12. The portion of the profit or of the selling price that may be customary in the  
2 particular business or in comparable businesses to allow for the use of the  
invention or analogous inventions.
- 3 13. The portion of the realizable profit that should be credited to the invention as  
4 distinguished from non-patented elements, the manufacturing process,  
business risks, or significant features or improvements added by the  
5 infringer.
- 6 14. The opinion testimony of qualified experts.
- 7 15. The amount that a licensor (such as the patentee) and a licensee (such as the  
8 infringer) would have agreed upon (at the time the infringement began) if  
both had been reasonably and voluntarily trying to reach an agreement; that  
9 is, the amount which a prudent licensee- who desired, as a business  
proposition, to obtain a license to manufacture and sell a particular article  
10 embodying the patented invention- would have been willing to pay as a  
royalty and yet be able to make a reasonable profit and which amount  
11 would have been acceptable by a prudent patentee who was willing to grant  
a license.

12 Georgia-Pacific, 318 F. Supp. at 1120.

13 In his report, Dr. Kerr addresses all of the Georgia-Pacific factors. Most of them,  
14 however, inform the analysis only insofar as they suggest that an increase or a reduction of the  
15 royalty rate would be appropriate: they do not provide a starting point for the calculation. In the  
16 absence of any comparable Belkin licenses or information regarding a customary royalty in the  
17 business, Dr. Kerr turned to the licensing agreements Avocent entered into with other alleged  
18 infringers.<sup>3</sup> The licenses provided information regarding the method of calculation (a percentage  
19 of sales of both the patented product and associated peripherals), the nature and scope of the  
20 license (nonexclusive and unrestricted, but applying to the entire patent family), and the duration  
21 of the licenses. Although two of the licenses address situations that were only marginally  
22 relevant to the hypothetical negotiation occurring between Avocent and Belkin in 2001, Dr. Kerr

---

23  
24 <sup>3</sup> Dr. Kerr's report is based solely on the contents of the settlement and license agreements  
25 which Belkin received during discovery. Belkin's evidentiary objections are therefore overruled  
26 without prejudice to the issue being raised again if Avocent attempts to elicit testimony regarding the  
negotiations that led to the settlement agreements.

1 adopted the 5% royalty rate used in the more comparable Raritan license as the starting point for  
2 his analysis. Dr. Kerr concluded, however, that additional adjustments would have to be made.

3 Up to this point, Dr. Kerr's analysis easily satisfies Daubert and the relevant patent  
4 case law. The licenses Dr. Kerr reviewed are clearly related to the claimed invention and, to the  
5 extent Raritan's situation was different than Belkin's, further adjustments and fine-tuning based  
6 on other Georgia-Pacific factors (such as the invention's established profitability, Belkin's  
7 profits, the promotion of sales of related Belkin products, the expert's opinion, *etc.*) could be  
8 made to inform the outcome of the hypothetical negotiation. Instead of performing a nuanced  
9 analysis, however, Dr. Kerr mentions some of these factors, then simply multiplies the Raritan  
10 royalty rate by three. The theory is that the uncertainty arising from ongoing litigation regarding  
11 the validity of the patents-in-suit and infringement depressed the royalty rate Avocent was able  
12 to negotiate with Raritan. The multiplier is based on data showing that patent holders lose  
13 infringement suits in federal court two-thirds of the time, suggesting that Avocent was facing a  
14 significant downside risk to pursuing litigation and therefore agreed to a discounted royalty rate.  
15 While the concept of adjusting a settlement-related license agreement to account for litigation  
16 risk is not inherently objectionable (see Mondis Tech., Ltd. v. LG Elecs., Inc., 2011 WL  
17 2417367, at \*4-6 (E.D. Tex. June 14, 2011)), the adjustment must have some relationship to the  
18 patent at issue. In this case, there is no indication that Dr. Kerr's chosen method of adjustment is  
19 anything more than an arbitrary multiplier based on factors and statistics having nothing to do  
20 with the patents or parties in this case.

21 The Federal Circuit recently rejected a similar tool used in calculating royalty  
22 rates. Uniloc USA, Inc. v. Microsoft Corp., 632 F.3d 1292, 1311-18 (Fed. Cir. 2011). The  
23 "25% rule of thumb" had been used for many years as the starting point for royalty calculations,  
24 giving the patent holder 25% of profits per unit and allowing the infringer to retain 75% of the  
25 profits. The rule was developed based on observations of commercial licenses and had been  
26

1 confirmed by years of licensing and profit data across industries. Nevertheless, the Federal  
2 Circuit found that the resulting royalty rate was not sufficiently tied to the facts of the case  
3 before it and would therefore be unhelpful to the jury. Uniloc, 632 F.3d at 1315-16. The court  
4 noted that the 25 percent rule of thumb was “an abstract and largely theoretical construct” that  
5 did “not say anything about a particular technology, industry, or party.” Uniloc, 632 F.3d at  
6 1317. Because the 25% rate was not actually tied to the facts and circumstances of the case at  
7 hand, it would not assist the jury in determining what value the patented technology would have  
8 been assigned by the parties in the marketplace when infringement began.

9           The same can be said of Dr. Kerr’s multiplier. The fact that patent holders are  
10 successful in only 33% of cases nationwide tells us nothing about the actual or perceived  
11 strength of Avocent’s claims as it was negotiating the settlement with Raritan. If, in 2005,  
12 Avocent was besieged with infringers and facing millions of dollars in legal fees in order to  
13 enforce its patent rights in court, it may have been willing to accept a deeply discounted royalty  
14 to avoid litigation expenses and risks. On the other hand, if Avocent were sure of its patents,  
15 Raritan was earning significant profits by infringing, and it was Raritan that was seeking to  
16 avoid litigation, the 5% royalty rate may be accurate or even inflated. Dr. Kerr’s one-size-fits-all  
17 multiplier would treat all litigation settlements in the same way, regardless of the underlying  
18 facts. The Federal Circuit has found that such shortcuts are “arbitrary, unreliable, and  
19 irrelevant” and their use “fails to pass muster under Daubert . . . .” Uniloc, 632 F.3d at 1318.  
20 Although Dr. Kerr will be permitted to testify regarding his opinion that licenses negotiated in  
21 settlement of litigation are often discounted, he may not present his litigation-success-rate theory  
22 as a surrogate for facts and circumstances related to the patents-in-suit.<sup>4</sup>

---

25           <sup>4</sup> The Court has not considered Belkin’s argument, raised for the first time in reply, that the  
26 claimed invention was not the basis for consumer demand. Dkt. # 780 at 6.

1 For all of the foregoing reasons, the Court GRANTS in part Belkin's motion to  
2 exclude the testimony of Dr. Kerr (Dkt. # 735). Dr. Kerr will not be permitted to provide his  
3 opinion, based on his general litigation-success-rate theory, that the royalty rate in the negotiated  
4 license should be multiplied by three.

5  
6 Dated this 11th day of March, 2013.

7  
8 

9 Robert S. Lasnik  
10 United States District Judge  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26